This inventor holds 1 USPTO granted patent. Top assignee: Lu License Ab. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Thomas Lundbäck: Innovator in Hematopoietic Stem Cell Treatment
Introduction
Thomas Lundbäck is a notable inventor based in Kullavik, Sweden. He has made significant contributions to the field of medical research, particularly in the treatment of hypoproliferative disorders. His innovative work focuses on the use of specific inhibitors to address critical health issues.
Latest Patents
Lundbäck holds 1 patent for his invention titled "Compounds for treatment of hypoproliferative disorders." This patent relates to the use of CDK8 and/or CDK19 inhibitors in treating ribosomopathies, conditions characterized by a reduced number of hematopoietic stem cells and/or progenitor cells, as well as bone anabolic disorders.
Career Highlights
He is currently associated with Lu License AB, where he continues to advance his research and development efforts. His work has the potential to impact the treatment of various hematological conditions significantly.
Collaborations
Lundbäck collaborates with esteemed colleagues, including Johan Flygare and Lars Johansson, who contribute to his research endeavors.
Conclusion
Thomas Lundbäck is a pioneering inventor whose work in the treatment of hypoproliferative disorders showcases the importance of innovation in medical science. His contributions are paving the way for new therapeutic approaches that could benefit many patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile